Stryker earnings
Stryker's next results are expected on October 29, 2026. Watch whether Stryker clears delivery problems while containing the cash costs of recovery.
What has Stryker guided for 2026?
On July 30, Stryker narrowed its forecast for the year ending December 2026. It expects organic sales growth of 8.3%–9.3%. “Organic” means growth from the existing business after removing currency movements, acquisitions and divestitures. It expects adjusted diluted earnings per share of $14.95–$15.10. “Adjusted” earnings exclude selected costs that management considers unusual or less useful for judging ongoing operations, while diluted earnings per share includes potential shares from awards.
| Period guided | Low | High | Date given | |
|---|---|---|---|---|
| Organic net sales growth | Year to Dec 2026 | 8.3% | 9.3% | Jul 30, 2026 |
| Adjusted net earnings per diluted share | Year to Dec 2026 | 14.95 | 15.10 | Jul 30, 2026 |
What this means. Organic net sales growth means sales growth from the existing business, leaving out bought or sold businesses and currency changes.
Has Stryker kept its past promises?
Management’s operating promises provide a counterweight. Stryker expanded adjusted operating margin by 110 basis points in 2024 and another 100 in 2025, meeting its stated improvement goal. It delivered 10.3% organic sales growth and adjusted earnings per share of US$13.63 against its original 2025 outlook.
What has Stryker's revenue and profit trend been?
Revenue rose to $6,589 million, with organic growth of 9.0% and flat pricing. Operating income reached $1,659 million, while net income reached $1,276 million. The main question is not whether the quarter improved, but how much of that improvement can recur.
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6,589 | 6,020 | 7,171 | 6,057 | 6,022 | 5,866 | 6,436 | 5,494 |
| Gross margin | 68.3% | 63.3% | 64.5% | 63.6% | 63.8% | 63.8% | 64.9% | 64.0% |
| Operating income | 1,659 | 936 | 1,804 | 1,135 | 1,113 | 837 | 581 | 1,085 |
| Net income | 1,276 | 745 | 849 | 859 | 884 | 654 | 546 | 834 |
| EPS, diluted | 3.30 | 1.93 | 2.20 | 2.22 | 2.29 | 1.69 | 1.41 | 2.16 |
| = Free cash flow | 1,059 | 415 | 1,875 | 1,353 | 928 | 127 | 1,665 | 1,304 |
What this means. Each quarter's cash numbers stand alone, so the second and third quarters are not totals for the year so far.
What should you watch in Stryker's next results?
The decisive evidence will be whether Stryker clears its delivery problems while containing the cash costs of recovery and its tax dispute.
Stryker confirmed October 29 as the next results date. Another milestone is Pangea’s planned full European commercial launch in the fourth quarter. Pangea is a trauma-plating system used to stabilize fractures. Its progress will show whether a limited launch can become wider commercial use.